M34 Cardiovascular Safety of Nintedanib in Subgroups by Cardiovascular Risk at Baseline in the Tomorrow and Inpulsis Trials

doi 10.1136/thoraxjnl-2017-210983.478
Full Text
Abstract

Available in full text

Date
Authors

Unknown

Publisher

BMJ Publishing Group Ltd and British Thoracic Society

Related search

Testing Cardiovascular Drug Safety and Efficacy in Randomized Trials

Circulation Research
Cardiovascular MedicinePhysiologyCardiology
2014English

Cardiovascular Efficacy and Safety of Bococizumab in High-Risk Patients

New England Journal of Medicine
Medicine
2017English

Managing Cardiovascular Risk in Type 2 Diabetes: What Do the Cardiovascular Outcome Trials Mean for Australian Practice?

Diabetes Therapy
Internal MedicineEndocrinologyMetabolismDiabetes
2019English

Effect of Nintedanib in Subgroups of Idiopathic Pulmonary Fibrosis by Diagnostic Criteria

American Journal of Respiratory and Critical Care Medicine
PulmonaryCritical CareRespiratory MedicineIntensive Care Medicine
2017English

Cardiovascular Safety of Exercise in the Elderly

Japanese Journal of Physical Fitness and Sports Medicine
Sports MedicinePhysical TherapySports ScienceOrthopedicsSports TherapyRehabilitation
2003English

Cardiovascular Risk Factors Associated With Lower Baseline Cognitive Performance in HIV-positive Persons

Neurology
Neurology
2010English

Prevalence of Abdominal Aortic Aneurysms in the General Population and in Subgroups at High Cardiovascular Risk in Italy. Results of the RoCAV Population Based Study

European Journal of Vascular and Endovascular Surgery
SurgeryCardiovascular MedicineCardiology
2018English

Are Men at Risk? The Role of Testosterone in Cardiovascular Morbidity

Pulmonary Circulation
PulmonaryRespiratory Medicine
2012English

The Future of Imaging in Cardiovascular Disease Intervention Trials

Current Opinion in Lipidology
NutritionGeneticsCell BiologyMolecular BiologyCardiologyEndocrinologyCardiovascular MedicineDieteticsMetabolismDiabetes
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2026 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy